Search Results

LIPOGEMS ANNOUNCES LAST PATIENT ENROLLED IN THE U.S. FDA IDE ARISE STUDY FOR THE TREATMENT OF KNEE OSTEOARTHRITIS

Lipogems announces it has completed enrollment in the ARISE I U.S. FDA IDE study, which aims to examine MicroFat versus corticosteriod injection for the treatment of Knee Osteoarthritis (OA).

April 10, 2024

·

2 min read

LIPOGEMS ANNOUNCES FIRST PATIENT ENROLLED IN THE SECOND U.S. FDA IDE STUDY FOR THE TREATMENT OF KNEE OSTEOARTHRITIS

Lipogems, a clinical stage- global medical technology company, announces the first patient enrolled in the ARISE II U.S. FDA IDE research study, which aims to examine investigational MicroFat versus saline injection for the treatment of Knee Osteoarthritis (OA).

April 5, 2024

·

2 min read

BioMidwest

Lipogems® Announces 140 independent Peer Reviewed Publications with 5 years of follow up in orthopaedics

Lipogems announced that there are now 140 peer reviewed publications supporting Lipogems’ MicroFat with 5 years of follow up in orthopaedics.

September 21, 2023

·

2 min read

U.S. FDA GRANTS LIPOGEMS® SECOND IDE APPROVAL FOR A CLINICAL TRIAL ON THE TREATMENT FOR KNEE OA

The U. S. Food and Drug Administration (FDA) has awarded Lipogems another Investigational Device Exemption (IDE) study for the use of MicroFat for the treatment of knee osteoarthritis (OA).

October 4, 2023

·

2 min read

LIPOGEMS ANNOUNCES FIRST PATIENT ENROLLED IN THE U.S. ARISE STUDY FOR THE TREATMENT OF KNEE OSTEOARTHRITIS

Lipogems, a clinical stage- global medical technology company, announces the first patient enrolled on January 13, 2023, in the ARISE U.S. FDA IDE study, which aims to examine MicroFat versus corticosteroid injection for the treatment of Knee Osteoarthritis (OA).

January 13, 2023

·

2 min read

LIPOGEMS RAISES €12.5M ($13.2M) TO ACCELERATE THE EXPANSION IN KNEE OSTEOARTHRITIS

Lipogems today announces it has raised €12.5M (approx. $13.2M ) in growth capital in 2022 to support the recent FDA approved IDE Studies for a separate and specific indication in Knee Osteoarthritis (OA).

December 23, 2022

·

3 min read

LIPOGEMS® RECEIVES IDE APPROVAL FROM THE U.S. FDA TO BEGIN A PIVOTAL CLINICAL STUDY ON THE SAFETY AND EFFECTIVENESS OF THE LIPOGEMS SYSTEM FOR THE TREATMENT OF KNEE OSTEOARTHRITIS

Lipogems is pleased to announce the unconditional approval by the U.S. Food and Drug Administration (FDA) to conduct an Investigational Device Exemption (IDE) study for treatment of knee osteoarthritis (OA) compared to corticosteroids for a period of 12 months.

June 9, 2022

·

2 min read

Business

Lipogems Provides Orthopaedic Patients With Another Option To Major Invasive Surgery

The Lipogems system is leading the way in reparative medicine by providing patients another option to major, invasive surger

January 14, 2019

·

2 min read

Business

LIPOGEMS Announces Milestone of 35,000 Procedures Performed For Patients Between Conservative Therapy and Major, Invasive Surgery

LIPOGEMS, an innovative medtech company with a leading and propriety adipose tissue system technology announces that it has achieve a major milestone of 35,000 procedures globally.

June 11, 2019

·

3 min read

Business

Lipogems Provides an FDA Cleared Option For Patients Between Conservative Therapy and Major, Invasive Surgery

The Lipogems system is leading the way in orthopaedic medicine by assisting patients who fall in the “treatment gap” between conservative therapies and major, surgical intervention

March 14, 2019

·

3 min read